Adrenergic alpha-2 Receptor Agonists
"Adrenergic alpha-2 Receptor Agonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that bind to and activate ADRENERGIC ALPHA-2 RECEPTORS.
| Descriptor ID |
D058647
|
| MeSH Number(s) |
D27.505.519.625.050.100.100.200 D27.505.696.577.050.100.100.200
|
| Concept/Terms |
Adrenergic alpha-2 Receptor Agonists- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha 2 Receptor Agonists
- Adrenergic alpha2-Agonists
- Adrenergic alpha2 Agonists
- alpha2-Agonists, Adrenergic
- Adrenergic alpha-2 Agonists
- Adrenergic alpha 2 Agonists
- Agonists, Adrenergic alpha-2
- alpha-2 Agonists, Adrenergic
- Adrenergic alpha-2 Receptor Agonist
- Adrenergic alpha 2 Receptor Agonist
|
Below are MeSH descriptors whose meaning is more general than "Adrenergic alpha-2 Receptor Agonists".
Below are MeSH descriptors whose meaning is more specific than "Adrenergic alpha-2 Receptor Agonists".
This graph shows the total number of publications written about "Adrenergic alpha-2 Receptor Agonists" by people in this website by year, and whether "Adrenergic alpha-2 Receptor Agonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 1 | 2 |
| 2018 | 1 | 1 | 2 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adrenergic alpha-2 Receptor Agonists" by people in Profiles.
-
Deeb W, Malaty IA, Mathews CA. Tourette disorder and other tic disorders. Handb Clin Neurol. 2019; 165:123-153.
-
Fetterly TL, Basu A, Nabit BP, Awad E, Williford KM, Centanni SW, Matthews RT, Silberman Y, Winder DG. a2A-Adrenergic Receptor Activation Decreases Parabrachial Nucleus Excitatory Drive onto BNST CRF Neurons and Reduces Their Activity In Vivo. J Neurosci. 2019 01 16; 39(3):472-484.
-
Harris NA, Isaac AT, G?nther A, Merkel K, Melchior J, Xu M, Eguakun E, Perez R, Nabit BP, Flavin S, Gilsbach R, Shonesy B, Hein L, Abel T, Baumann A, Matthews R, Centanni SW, Winder DG. Dorsal BNST a2A-Adrenergic Receptors Produce HCN-Dependent Excitatory Actions That Initiate Anxiogenic Behaviors. J Neurosci. 2018 10 17; 38(42):8922-8942.
-
McCarren HS, Chalifoux MR, Han B, Moore JT, Meng QC, Baron-Hionis N, Sedigh-Sarvestani M, Contreras D, Beck SG, Kelz MB. a2-Adrenergic stimulation of the ventrolateral preoptic nucleus destabilizes the anesthetic state. J Neurosci. 2014 Dec 03; 34(49):16385-96.
-
Singh R, Visintainer PF. Adjunctive therapy for neonatal abstinence syndrome: why not personalize it for each infant based on their in-utero exposure? J Perinatol. 2014 Jul; 34(7):575-6.
-
Surran B, Visintainer P, Chamberlain S, Kopcza K, Shah B, Singh R. Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. J Perinatol. 2013 Dec; 33(12):954-9.
-
Egli RE, Kash TL, Choo K, Savchenko V, Matthews RT, Blakely RD, Winder DG. Norepinephrine modulates glutamatergic transmission in the bed nucleus of the stria terminalis. Neuropsychopharmacology. 2005 Apr; 30(4):657-68.